ANI Pharmaceuticals (FRA:BSFA) Total Liabilities: €743.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BSFA ANI Pharmaceuticals Inc FRA:BSFA
78 GF Score
Price €66.00
GF Value €83.99
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Total Liabilities?

ANI Pharmaceuticals FRA:BSFA -2.94% 78 Total Liabilities is €743.6 Mil as of Mar. 2026. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €83.99 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ANI Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was €743.6 Mil.

ANI Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 (€768.79 Mil) to Dec. 2025 (€768.30 Mil) and declined from Dec. 2025 (€768.30 Mil) to Mar. 2026 (€743.62 Mil).

ANI Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (€409.74 Mil) to Dec. 2024 (€817.42 Mil) but then declined from Dec. 2024 (€817.42 Mil) to Dec. 2025 (€768.30 Mil).

ANI Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Total Liabilities Chart

ANI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 365.38 397.94 409.74 817.42 768.30

ANI Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 785.29 764.17 768.79 768.30 743.62
FRA:BSFA
78GF Score
ANI Pharmaceuticals Inc FRA:BSFA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ANI Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=237.508+(512.201+18.595
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=768.3

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1230.082-461.778
=768.3

ANI Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=207.176+(514.21+22.229
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=743.6

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1230.004-486.389
=743.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €743.6 Mil mean?
ANI Pharmaceuticals (FRA:BSFA) has a Total Liabilities of €743.6 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ANI Pharmaceuticals and its competitors.
Is ANI Pharmaceuticals' Total Liabilities too high?
ANI Pharmaceuticals' current Total Liabilities is €743.6 Mil. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Total Liabilities compare to TRLV and AMLX?
ANI Pharmaceuticals' Total Liabilities of €743.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ANI Pharmaceuticals and its competitors. ANI Pharmaceuticals's current Total Liabilities is €743.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.99, compared to a current price of €66.00 — trading 21.4% below its estimated fair value. The current Total Liabilities is €743.6 Mil. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Total Liabilities is €743.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of €66.00 is trading 21.4% below its estimated GF Value™ of €83.99. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for FRA:BSFA:

  • Total Liabilities: €743.6 Mil
  • GF Value™: €83.99 vs. price of €66.00 (21.4% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANI Pharmaceuticals Business Description

Other Exchanges ANIP:USA
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score

Get the complete analysis for FRA:BSFA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.00
Price
€83.99
GF Value